Trial Profile
A prospective, open label, controlled, multicentre trial to assess the effect of an induction regimen of Neoral (R), Myfortic (R) and corticosteroids, followed by administration of Certican (R) together with withdrawal of Neoral (R) on inflammatory and cardiovascular markers in kidney transplant recipients.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 22 Jun 2016
Price :
$35
*
At a glance
- Drugs Ciclosporin (Primary) ; Everolimus (Primary) ; Mycophenolate sodium (Primary) ; Prednisolone (Primary)
- Indications Renal transplant rejection
- Focus Pharmacodynamics
- Acronyms REVIVE
- 08 Jun 2016 Status changed from not yet recruiting to completed.
- 17 Aug 2011 New trial record